Omitting Radiotherapy in Early Positron Emission Tomography–Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial

John M.M. Raemaekers, Marc P.E. André, Massimo Federico, Theodore Girinsky, Reman Oumedaly, Ercole Brusamolino,† Pauline Brice, Christophe Fermé, Richard van der Maazen, Manuel Gotti, Reda Bouabdallah, Catherine J. Sebban, Yolande Lievens, Allessandro Re, Aspasia Stamatoullas, Gustaaf van Imhoff, Tiana Raveloarivahy, Monica Bellei, Thierry van der Borght, Stephane Bardet, Annibale Versari, Martin Hutchings, Michel Meignan, and Catherine Fortpied

ABSTRACT

Purpose
Combined-modality treatment is standard treatment for patients with clinical stage I/II Hodgkin lymphoma (HL). We hypothesized that an early positron emission tomography (PET) scan could be used to adapt treatment. Therefore, we started the randomized EORTC/LYSA/FIL Intergroup H10 trial evaluating whether involved-node radiotherapy (IN-RT) could be omitted without compromising progression-free survival in patients attaining a negative early PET scan after two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) as compared with standard combined-modality treatment.

Patients and Methods
Patients age 15 to 70 years with untreated clinical stage I/II HL were eligible. Here we report the clinical outcome of the preplanned interim futility analysis scheduled to occur after documentation of 34 events in the early PET–negative group. Because testing for futility in this noninferiority trial corresponds to testing the hypothesis of no difference, a one-sided superiority test was conducted.

Results
The analysis included 1,137 patients. In the favorable subgroup, 85.8% had a negative early PET scan (standard arm, one event vs experimental arm, nine events). In the unfavorable subgroup, 74.8% had a negative early PET scan (standard arm, seven events vs experimental arm, 16 events).

The independent data monitoring committee concluded it was unlikely that we would show noninferiority in the final results for the experimental arm and advised stopping random assignment for early PET–negative patients.

Conclusion
On the basis of this analysis, combined-modality treatment resulted in fewer early progressions in clinical stage I/II HL, although early outcome was excellent in both arms. The final analysis will reveal whether this finding is maintained over time.

INTRODUCTION

Standard treatment for patients with clinical stage I/II Hodgkin lymphoma (HL) consists of the combination of chemotherapy (mostly ABVD [doxorubicin, bleomycin, vinblastine, and dacarbazine]) followed by radiotherapy (RT). Despite the reduction of RT fields from extended field to involved node (IN), there has been a continuing attempt to omit RT to reduce late complications. Prognostic factors have yet to reproducibly identify those who can be treated with chemotherapy alone. Patients have a significantly higher risk of recurrence after chemotherapy alone than after combined-modality...
treatment.5-7 Because of adequate but intensive salvage treatment, overall survival does not differ significantly. The right balance between initial cure through combined-modality treatment—accepting a higher risk of late complications—and a higher recurrence rate after omitting RT in subsets of patients who will subsequently need intensive salvage treatment (often including autologous stem-cell transplantation) is a matter of an unsettled debate.8-12 Early [18F]fluorodeoxyglucose–positron emission tomography (PET) scanning after two cycles of chemotherapy provides prognostic information on final outcome; patients who attain a negative early PET scan after two cycles of ABVD (or similar) chemotherapy have better progression-free survival (PFS) than those with a positive early PET scan, when the initially planned treatment is completed.13-15 Patients with a negative early PET scan might be treated less intensively in view of the excellent prognosis. We hypothesized that patients with stage I/II disease who achieve a negative early PET scan could be spared additional RT. In contrast, those with a positive early PET scan might benefit from early treatment intensification16 from ABVD to BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) escalated.

We initiated a randomized controlled phase III intergroup trial to evaluate primarily the efficacy of chemotherapy alone versus combined-modality treatment in patients with a negative early PET scan after two cycles of ABVD. Second, we evaluated the efficacy of intensification of chemotherapy in patients with a positive early PET scan after two cycles of ABVD.17 A preplanned interim analysis was conducted after a predefined number of events had occurred during the course of the trial to detect possible worse early outcome of the experimental arm. Our report describes the results of this preplanned interim futility analysis performed among patients with a negative early PET scan.

**PATIENTS AND METHODS**

**Study Design**

In October 2006, the European Organisation for Research and Treatment of Cancer, Lymphoma Study Association, and Fondazione Italiana Linfomi (FIL), joined in March 2008. The main objective was to evaluate whether IN-RT could be omitted without loss of efficacy in terms of PFS in patients who attain a negative early PET scan after two cycles of ABVD.18 The secondary objective was to evaluate whether intensification from ABVD to BEACOPP escalated would increase PFS in patients who did not achieve a negative early PET scan. Eligibility criteria included previously untreated patients with histologically proven classical HL, supraclavicular nodes, Ann Arbor stage I/II disease, age 15 to 70 years, WHO performance status of 0 to 3, and written informed consent. The number of chemotherapy cycles depended on the prognostic subgroup: favorable or unfavorable (Fig 1).19,20

The study was approved by the respective scientific boards and national ethics committees and was registered in ClinicalTrials.gov.20 Patients were centrally randomly assigned to receive either standard or investigational treatment. A minimization technique was used for treatment allocation in each prognostic subgroup (favorable vs unfavorable), stratifying by institution, Ann Arbor stage (I vs II), and availability of baseline PET.

**Early PET Scan**

A prospective central reading of the early PET scan was planned in the protocol.21 For technical reasons, centralised review for the LYSA group started from the initiation of the trial, and for EORTC/FIL groups, it occurred from 2008 onward. In case of absence of a timely (< 72 hours) centralized reading, the local result of the early PET scan was decisional for further treatment in the experimental arm (first PET interpretation). A blinded second central PET review (second central review) was performed retrospectively after the recommendations of the independent data monitoring committee (IDMC) by four experts on the scans of 52 patients with events (including patients with early PET–negative and early PET–positive scans) and 52 randomly selected patients without events using a dedicated workstation (POSITOSCOPE; Keosys, Saint-Herblain, France). Twenty of these 104 scans could not be used for second central review for logistic or technical reasons; 84 were compared with the results of the first review (first central interpretation). Two experts from LYSA reviewed EORTC/FIL scans and vice versa. PET images were scored according to the International Harmonisation Project criteria,22 which were the generally accepted criteria for post-treatment assessment (metabolism index ≥ 50% to 85% and 80%, respectively), the resulting noninferiority margins corresponding to scores 1 (no uptake) and 2 (uptake ≤ midline) on the 5-point Deauville scale.23

**Statistics**

The primary endpoint was PFS, defined—from the date of random assignment to date of progression—as relapse after previous complete remission or progression after reaching partial remission (≥ 50% decrease and resolution of B symptoms and no new lesions) or progressive disease (50% increase from nadir of any previous partial remission lesions or appearance of new lesions) on computed tomography scan measurements during protocol treatment or death resulting from any cause, whichever occurred first (censoring rules are given in the Data Supplement).

The primary objective of the study was to evaluate whether the investigational treatment without RT was noninferior to the standard combined-modality approach in terms of PFS. Each prognostic subgroup (favorable and unfavorable) was to be analyzed separately, using a log-rank test stratified by stage (I vs II) and availability of baseline PET, with a one-sided significance level of .025. Assuming a 5-year PFS in the standard arm of 95% for the favorable subgroup and 90% for the unfavorable subgroup, and allowing for a decrease of 10% (to 85% and 80%, respectively), the resulting noninferiority margins...
for the hazard ratios (HRs) were 3.2 and 2.1 for favorable and unfavorable subgroups, respectively. A total of 26 and 63 events (progressions or deaths) for favorable and unfavorable subgroups, respectively, were required for 80% power to reject the null hypothesis of inferiority if the true HR were equal to 1.0. Sample size computations allowed for one interim analysis for futility. For the whole trial, we had planned to recruit 608 and 720 patients, respectively, in 4.5 years. The final analysis was scheduled to be performed after an additional follow-up of 2 years. No adjustment for multiplicity was made, because the trial is considered as two independent studies (favorable/unfavorable) embed- ded in the same protocol.

An interim futility analysis24-26 of the primary end point was scheduled after documentation of 12 and 22 events (progression, relapse, or death) for early PET–negative favorable and unfavorable subgroups, respectively. It was estimated that at that time point, roughly two thirds of the total number of required patients would be accrued. The purpose of the interim futility analysis was to stop the recruitment of favorable and unfavorable patients in case of inferiority of the investigational arm. Because testing for futility in this noninferiority trial corresponds to testing the hypoth- esis of no difference between the two arms, a one-sided superiority test was conducted, with a significance level determined by a Lan-DeMets spending function (Pocock like) based on the total error of 0.20 (details are given in the Data Supplement). Stopping boundaries were comp- uted using East software (version 5.3; Cytel, Cambridge, MA). Statis- tical analysis of the study data was conducted using SAS software (version 9.1; SAS Institute, Cary, NC). The results of the early PET–positive group of patients lie outside the scope of this article.

**RESULTS**

The database was locked for the interim analysis at April 19, 2010. The analysis was based on patients randomly assigned on or before August 31, 2009, at which time a total of 1,137 patients had been randomly assigned, with 61%, 25%, and 14% recruited by LYSa, EORTC, and FIL respectively. Median follow-up at the clinical cutoff date (October 31, 2009) was 1.1 years.

A baseline PET scan was performed in 93.2% of patients. Figure 2 shows the flowchart for patients enrolled in the interim analysis (fa- vorable subgroup, n = 444; unfavorable subgroup, n = 693). In the favorable subgroup, 85.8% (381 of 444) had a negative early PET scan, and in the unfavorable subgroup, 74.8% (519 of 693) had one. The frequency of early PET–negative scans was somewhat higher in the experimental arm (81.2%) than in the standard arm (77.2%). Clinical characteristics and durations of follow-up were well balanced between the standard and experimental arms (Table 1). The interim futility analysis was performed among 1,124 of the 1,137 patients. Eleven patients did not complete the first two cycles of ABVD or had no early PET scan performed, and for two patients, no validated data were available.

**Favorable Early PET–Negative Group**

In the standard arm, 188 patients were included; in the experimental group, 193 patients (Table 2). A total of 10 events occurred (standard arm, one event vs experimental arm, nine events). All events were disease progressions (no deaths). On the basis of the actual information fraction (10 of 26 events required for final analysis) and the resulting one-sided significance level to perform the statistical test (.102), futility was declared ($P = .017$); that is, on the basis of this analysis, it was unlikely that we could show equivalent efficacy between the standard and experimental treatments when continuing accrual to the originally planned total numbers. The estimated HR was 9.36 (79.6% CI, 2.45 to 35.73). PFS rates at 1 year were 100.0% and 94.9% in the standard and experimental arms, respectively.

**Unfavorable Early PET–Negative Group**

In the standard arm, 251 patients were included; in the experimental group, 268 patients (Table 2). A total of 23 events occurred (standard arm, seven events vs experimental arm, 16
One patient died as a result of toxicity without signs of progression; all remaining events were progressions. On the basis of the actual information fraction (23 of 63 events required for final analysis) and the resulting one-sided significance level to perform the statistical test (.098), futility was declared ($P_{H11005}/H11021.026$ [ie, $H11021/110.098$]). The estimated HR was 2.42 (90.4% CI, 1.35 to 4.36). PFS rates at 1 year were 97.3% and 94.7% in the standard and experimental arms, respectively.

### Conclusion of IDMC and Recommendations

Because the interim futility analysis showed statistical significance for PFS in both favorable and unfavorable early PET–negative groups, the IDMC recommended closing the study for continued accrual in the early PET–negative experimental arm. Moreover, it recommended changing treatment in patients with early PET–negative scans who were randomly assigned to the experimental arm and had not yet completed treatment from chemotherapy.

### Table 1. Clinical Characteristics of Patients With Early PET-Negative Disease

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Favorable</th>
<th></th>
<th></th>
<th>Unfavorable</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Standard (n = 188)</td>
<td>Standard (n = 251)</td>
<td>Experimental (n = 193)</td>
<td>Experimental (n = 268)</td>
<td>Total (N = 900)</td>
<td></td>
</tr>
<tr>
<td>No. %</td>
<td>No. %</td>
<td>No. %</td>
<td>No. %</td>
<td>No. %</td>
<td>No. %</td>
<td>No. %</td>
</tr>
<tr>
<td>Age, years</td>
<td>29.5</td>
<td>16-49</td>
<td>31</td>
<td>15-49</td>
<td>33</td>
<td>16-70</td>
</tr>
<tr>
<td>Range</td>
<td>16-49</td>
<td>31</td>
<td>33</td>
<td>15-49</td>
<td>31</td>
<td>16-70</td>
</tr>
<tr>
<td>Male sex</td>
<td>107</td>
<td>56.9</td>
<td>97</td>
<td>50.3</td>
<td>124</td>
<td>49.4</td>
</tr>
<tr>
<td>Ann Arbor clinical stage I</td>
<td>44</td>
<td>23.4</td>
<td>43</td>
<td>22.3</td>
<td>28</td>
<td>11.2</td>
</tr>
<tr>
<td>B symptoms</td>
<td>13</td>
<td>6.9</td>
<td>13</td>
<td>6.7</td>
<td>90</td>
<td>35.9</td>
</tr>
<tr>
<td>No. of nodal areas</td>
<td>Median</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>1-3</td>
<td>1-5</td>
<td>1-5</td>
<td>1-5</td>
<td></td>
</tr>
<tr>
<td>Bulky mediastinum</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
<td>101</td>
<td>40.2</td>
</tr>
<tr>
<td></td>
<td>106</td>
<td>39.5</td>
<td>207</td>
<td>23.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MT ratio</td>
<td>Median</td>
<td>0.3</td>
<td>0.3</td>
<td>0.3</td>
<td>0.3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>0-0.3</td>
<td>0-0.7</td>
<td>0-0.93</td>
<td>0-0.93</td>
<td></td>
</tr>
<tr>
<td>ESR, mm/hr</td>
<td>Median</td>
<td>14</td>
<td>14</td>
<td>48</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>0.8-48</td>
<td>0.3-49</td>
<td>0.143</td>
<td>0.140</td>
<td>0-143</td>
</tr>
<tr>
<td>No B symptoms</td>
<td>Median</td>
<td>14</td>
<td>14</td>
<td>18</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>0.3-49</td>
<td>1-48</td>
<td>5-29</td>
<td>0-120</td>
<td>0-120</td>
</tr>
<tr>
<td>B symptoms</td>
<td>Median</td>
<td>18</td>
<td>20</td>
<td>60</td>
<td>47</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>0.8-29</td>
<td>0-120</td>
<td>10-143</td>
<td>0-143</td>
<td>0.3-143</td>
</tr>
<tr>
<td>Baseline PET</td>
<td>Median</td>
<td>176</td>
<td>93.6</td>
<td>180</td>
<td>93.3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>0.3-49</td>
<td>0.3-120</td>
<td>0.143</td>
<td>0.140</td>
<td>0.3-143</td>
</tr>
<tr>
<td>WHO PS 1-2</td>
<td>Median</td>
<td>16</td>
<td>8.5</td>
<td>9</td>
<td>4.7</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>0.1-2.7</td>
<td>0.1-2.9</td>
<td>0.1-2.9</td>
<td>0.1-2.7</td>
<td></td>
</tr>
<tr>
<td>Duration of follow–up, years</td>
<td>Median</td>
<td>1.1</td>
<td>1.0</td>
<td>1.1</td>
<td>1.1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>0.1-2.7</td>
<td>0.1-2.9</td>
<td>0.1-2.9</td>
<td>0.1-2.9</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ESR, erythrocyte sedimentation rate; MT, mediastinum to thorax; PET, positron emission tomography; PS, performance status.

### Table 2. Results of Interim Analysis in Patients With Early PET-Negative Disease

<table>
<thead>
<tr>
<th>Subset</th>
<th>No. of Patients</th>
<th>No. of Observed Events</th>
<th>HR</th>
<th>Adjusted CI*</th>
<th>$P_f$</th>
<th>%</th>
<th>Adjusted CI*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Favorable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Standard</td>
<td>188</td>
<td>1</td>
<td>1.00</td>
<td>2.45 to 35.73</td>
<td>94.93</td>
<td>91.89 to 96.85</td>
<td></td>
</tr>
<tr>
<td>Experimental</td>
<td>193</td>
<td>9</td>
<td>9.36</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unfavorable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Standard</td>
<td>251</td>
<td>7</td>
<td>1.00</td>
<td>1.35 to 4.36</td>
<td>94.70</td>
<td>92.11 to 96.46</td>
<td></td>
</tr>
<tr>
<td>Experimental</td>
<td>268</td>
<td>16</td>
<td>2.42</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: HR, hazard ratio; PET, positron emission tomography; PFS, progression-free survival. *Confidence level adjusted to significance level used in interim test: 79.6% CI for favorable group and 80.4% CI for unfavorable group. †One-sided Wald-test $P$ value of superiority test.
The interim analysis of early PET–positive patients did not meet the criteria for conclusion on the superiority of treatment intensification. Hence, the second question of the trial has not yet been answered at this interim analysis.

Because not all patients underwent a prospective first central review, and because of the somewhat higher frequency of early PET negativity in the experimental arm as compared with the standard arm, the IDMC recommended performing a blinded second central review before results of the interim analysis could be reported. This second central review was performed on early PET scans of all patients experiencing an event and, as a control group, randomly selected early PET scans of patients who did not experience an event.

**Actions Taken on IDMC Recommendations**

The study investigators were informed by letter on the main conclusion of the interim analysis (ie, stopping accrual in early PET–negative part of trial). It was advised that all patients who had already been randomly assigned to the experimental arm but who had not yet completed treatment or who had completed chemotherapy within the last 6 weeks be switched to standard-arm treatment (ie, chemotherapy plus IN-RT). New patients could still be enrolled and randomly assigned in the trial, but only for the early PET–positive part of the study. Therefore, patients with an early PET–negative scan after two cycles of ABVD would receive the combined-modality treatment, even if they had been assigned to the experimental arm at the start of the trial. Only patients with an early PET–positive scan remained in their assigned arm.

To ensure sufficient statistical power to address the early PET–positive objective of the trial, we decided to increase the number of required patients for the early PET–positive group from 248 to 335 patients. This revision was recommended by a senior statistician independent from the study team who had access to the actual recruitment rate and observed event rate in the standard arm. The study was closed to recruitment in June 2011, with a total of 1,952 randomly assigned patients.

**Second Central Review of Early PET Scans**

Overall, 70% of patients were early PET negative at the first PET interpretation. At the second central review, six patients included in the interim analysis of early PET–negative patients would have changed to early PET positive. Excluding these patients from the interim analysis, numbers of events in the favorable group changed from one versus nine to one versus seven; in the unfavorable group, numbers change from seven versus 16 to five versus 14. The IDMC concluded that considering these changes, the advantage for the standard arm persisted.

**DISCUSSION**

The prescheduled interim futility analysis of the first randomized trial, to our knowledge, on early PET scan–driven treatment adaptation in clinical stage I/II HL revealed that more early progressions occurred after chemotherapy alone than after standard chemotherapy plus IN-RT in early PET–negative patients. This conclusion held for both the favorable and unfavorable subsets of patients. Although the numbers of events were small, and the median follow-up time was short, the coordinating study team decided, in line with the conclusions of the IDMC, to stop enrollment in the early PET–negative part of the study and to maintain combined-modality treatment as standard for patients with early PET–negative scans. The results of the blinded second central review of early PET scans did not change these conclusions. Importantly, the overall early outcome, both in the standard and experimental arms, was excellent.

The objective of our H10 trial was to determine a robust clinical tool for selecting patients who could be spared the toxicity of RT without compromising tumor control. On the basis of the futility interim analysis, it was unlikely that the study would demonstrate noninferiority for chemotherapy alone in early PET–negative patients. Thus, omitting IN-RT in early PET–negative patients resulted in a higher percentage of early relapses than combined-modality treatment.

The interim futility analysis was designed to stop recruitment if there were significant signals of inferiority of the investigational arm as compared with the standard arm. Although this was the conclusion, some questions can be raised. Whether the interim analysis was premature, in the sense that follow-up time (median, 1.1 years) was short and the number of events small, can be argued. The noninferiority margin was based on the assumption that this difference in progression would outweigh the burden of late toxicity. Admittedly, both arms had excellent early outcomes, and large proportions of patients did well with ABVD alone. However, the main goal of our trial was to find the ideal tool for early detection of patients who do not need RT; in this setting, early PET scanning did not meet our objective. Another matter of debate is whether the choice of statistical criteria for declaring futility was sound. However, given the interim data, there was a low likelihood that the experimental treatment arm would be found to be noninferior to the standard arm had the trial continued. Given the accumulated data, and assuming the observed HR trend would be maintained during the remainder of the trial, the conditional power to demonstrate noninferiority at the final analysis was 0% in both favorable and unfavorable groups. In the rather optimistic scenario where HR would be equal to 1.0 during the remainder of the trial, the conditional power to demonstrate noninferiority would be 3% and 30% in favorable and unfavorable subgroups, respectively.

Several randomized studies comparing chemotherapy alone with combined-modality treatment without using early PET scans have reached comparable conclusions. The EORTC/GELA H9 study on patients with favorable clinical stage I/II disease showed a significantly higher relapse rate in patients receiving chemotherapy alone as compared with those who received 20–36-Gy involved-field RT. The Canadian-US Intergroup study, with a somewhat different risk-adapted design, also revealed higher risk of relapse in patients who did not undergo irradiation, although there were higher toxicity and death rates in the RT arm. It should be emphasized that subtotal nodal RT was used in this trial, an RT–strategy that has since been replaced by the less extensive IF-RT and, more recently, by IN-RT, as used in our H10 study. In a recent meta-analysis on combined-modality treatment versus chemotherapy alone, the combined approach resulted in improved tumor control as well as better overall survival. A survival advantage for combined-modality treatment compared with chemotherapy alone was demonstrated in a recent large population-based study.

A large proportion of patients with favorable clinical stage I/II disease can be treated with chemotherapy alone, as demonstrated in this trial. Patients who relapse after chemotherapy alone can often,
Radiotherapy in Early PET-Negative HL: Interim Analysis of H10 Trial

although not always, benefit from intensive salvage treatment. It re-
mains difficult, if not impossible, to balance the advantages of imme-
diate cure with increased toxicity against a higher relapse risk after les-
sofew intensive first-line treatment with its consequences for intensive
salvage therapy. Thus, the correct treatment strategy is in the eye of
the beholder. The recently completed UK RAPID LH2007 trial29 and
the ongoing German Hodgkin Study Group HD16 and HD17 random-
ized trials, will contribute to the positioning of early PET scanning.
Our interim analysis showed that the risk of early relapse in patients
not undergoing irradiation was significantly higher than that after
combined-modality treatment in early PET–negative patients, even
though both treatment approaches resulted in excellent early out-
come. Final trial analysis will reveal mature outcome data.

REFERENCES

1. Fermé C, Eghbali H, Meervalds JH, et al: Chemotherapy plus involved-field radiation in early-
therapy alone versus chemotherapy plus radio-
7. Thomas J, Fermé C, Noordijk E, et al: Results of the EORTC-GELA H9 randomized trials: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma. Haematologica 92, 2007 (abstr C010)
9. van der Maazen RV, Raemaekers JM: Chem-
otherapy and radiotherapy in Hodgkin’s lymphoma: Joining in or splitting up? Curr Opin Oncol 18:660-668, 2006
tive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s dis-
 ease. Haematologica 91:475-481, 2006
ity treatment in patients with supradiaphragmatic stage III Hodgkin’s lymphoma, for the Groupe d’Etude des Lymphomes de l’Adulte (GELA), Eu-
ropean Organisation for the Research and Treat-
ment of Cancer (EORTC) Lymphoma Group and the Intergroupo Italiano Linfomi (III). Blood 114, 2009 (abstr 97)
18. Tubiana M, Henry-Amar M, van der Werf-
messing B, et al: A multivariate analysis of progno-
20. European Organisation for Research and Treatment of Cancer, Lymphoma Study Association, Intergroupo Italiano Linfomi: [18F]fluorodeoxyglu-
cose PET scan-guided therapy or standard therapy in treating patients with previously untreated stage I or stage II Hodgkin’s lymphoma. http://clinicaltrials-
gov/show/NCT00433433
ment of futility in clinical trials. Pharm Stat 5:273-
281, 2006
toring the ACTIVE-W trial: Some issues in moni-
27. Herbst C, Rehan FA, Brillant C, et al: Com-
bined modality treatment improves tumor control and overall survival in patients with early stage

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The author(s) indicated no potential conflicts of interest.

AUTHOR CONTRIBUTIONS

Conception and design: John M.M. Raemaekers, Marc P.E. André, Massimo Federico, Theodore Girinsky, Pauline Brice, Christophe Fermé, Richard van der Maazen, Reda Bouabdallah, Catherine J. Sebban, Yolande Lieveens, Pieterella J. Lugtenburg, Rene-Olivier Casasnovas, Gustaaf van Imhoff, Tiana Raveloarivahy, Annibale Versari, Catherine Fortpied

Administrative support: John M.M. Raemaekers, Michel Meignan, Catherine Fortpied


Collection and assembly of data: John M.M. Raemaekers, Marc P.E. André, Massimo Federico, Theodore Girinsky, Reman Oumenedly, Ercole Brusamolino, Manuel Gotti, Alessandro Re, Aspasia Stamatooula, Frank Morschhauser, Elisabetta Abruzzese, Pierre Olivier, Gustaaf van Imhoff, Tiana Raveloarivahy, Thierry van der Bortgh, Stephane Bardet, Michel Meignan, Catherine Fortpied

Data analysis and interpretation: John M.M. Raemaekers, Marc P.E. André, Massimo Federico, Theodore Girinsky, Ercole Brusamolino, Richard van der Maazen, Tiana Raveloarivahy, Monica Bellei, Thierry van der Bortgh, Stephane Bardet, Annibale Versari, Martin Hutchings, Catherine Fortpied

Manuscript writing: All authors

Final approval of manuscript: All authors


Affiliations

John M.M. Raemaekers and Richard van der Maazen, Radboud University Medical Center, Nijmegen; Piernella J. Lugtenburg, Erasmus University Medical Center, Rotterdam; Gustaaf van Imhoff, University Medical Centre Groningen, Groningen, the Netherlands; Marc P.E. André and Thierry van der Borght, Centre Hospitalier Universitaire (CHU) L’Université Catholique de Louvain Mont Godinne, Yvoir; Yolande Lievens, Ghent University Hospital, Ghent; Tiana Raveloarivahy and Catherine Fortpied, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Massimo Federico and Monica Bellei, University of Modena and Reggio Emilia, Modena; Ercole Brusamolino, Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan; Manuel Gotti, Fondazione IRCCS Policlinico San Matteo, Pavia; Allessandro Re, Spedali Civili Hospital, Brescia; Elisabetta Abruzzese, San Eugenio Hospital, Tor Vergata University, Rome; Annibale Versari, Arcispedale Santa Maria Nuova, IRCCS di Reggio Emilia, Reggio Emilia, Italy; Theodore Girinsky and Christophe Ferrand, Institut Gustave Roussy, Villejuif; Reman Oumedaly, CHU Caen; Stephane Bardet, Centre Francois Baclesse, Caen; Pauline Brice, Hôpital Saint-Louis, Paris; Reda Bouabdallah, Institut Paoli Calmette, Marseille; Catherine J. Sebban, Centre Léon Bérard, Lyon; Aspasia Stamatoullas, Centre Henri Becquerel, Rouen; Frank Morschhauser, CHU de Lille, Lille; Pierre Olivier, CHU Nancy, Nancy; Rene-Olivier Casasnovas, CHU de Dijon, Dijon; Michel Meignan, Hôpital Henri Mondor, Creteil, France; and Martin Hutchings, Rigshospitalet, Kopenhagen, Denmark.

2014 ASCO Annual Meeting

Join us for the 2014 ASCO Annual Meeting (May 30–June 3 in Chicago, IL), which brings together more than 25,000 oncology professionals from a wide range of specialties. Marking the 50th Anniversary of ASCO, this year’s theme is Science and Society... The Next 50 Years. As we embark on our next 50 years as an organization, we will reflect on the tremendous progress ASCO has made against cancer and look at the future of science in oncology. For more information, visit am.asco.org.

Each year, ASCO, in conjunction with our cosponsors, organizes a wide array of high-quality meetings, providing educational and scientific programs to advance your understanding of cancer. Join us for one or more of ASCO’s meetings to interact with oncology experts, network with colleagues, and earn CME credit.
Acknowledgment
We thank all investigators of the participating groups who actively entered patients in this trial, data managers, supporting crew, and, last but not least, all patients who participated.